HRP20010045B1 - PROCESS FOR OBTAINING HMG-CoA REDUCTASE INHIBITORS OF HIGH PURITY - Google Patents

PROCESS FOR OBTAINING HMG-CoA REDUCTASE INHIBITORS OF HIGH PURITY

Info

Publication number
HRP20010045B1
HRP20010045B1 HR20010045A HRP20010045A HRP20010045B1 HR P20010045 B1 HRP20010045 B1 HR P20010045B1 HR 20010045 A HR20010045 A HR 20010045A HR P20010045 A HRP20010045 A HR P20010045A HR P20010045 B1 HRP20010045 B1 HR P20010045B1
Authority
HR
Croatia
Prior art keywords
coa reductase
reductase inhibitors
hmg
purity
chemical synthesis
Prior art date
Application number
HR20010045A
Other languages
English (en)
Inventor
Grahek Rok
Milivojevi� Du�an
Bastarda Andrej
Original Assignee
Lek Pharmaceutical And Chemical Company D.D.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceutical And Chemical Company D.D. filed Critical Lek Pharmaceutical And Chemical Company D.D.
Publication of HRP20010045A2 publication Critical patent/HRP20010045A2/hr
Publication of HRP20010045B1 publication Critical patent/HRP20010045B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/422—Displacement mode
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/48—Separation; Purification; Stabilisation; Use of additives
    • C07C67/52—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
HR20010045A 1998-09-18 2001-01-16 PROCESS FOR OBTAINING HMG-CoA REDUCTASE INHIBITORS OF HIGH PURITY HRP20010045B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI9800241A SI20072A (sl) 1998-09-18 1998-09-18 Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze
PCT/IB1999/001553 WO2000017182A1 (en) 1998-09-18 1999-09-17 PROCESS FOR OBTAINING HMG-CoA REDUCTASE INHIBITORS OF HIGH PURITY

Publications (2)

Publication Number Publication Date
HRP20010045A2 HRP20010045A2 (en) 2001-12-31
HRP20010045B1 true HRP20010045B1 (en) 2005-08-31

Family

ID=20432332

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010045A HRP20010045B1 (en) 1998-09-18 2001-01-16 PROCESS FOR OBTAINING HMG-CoA REDUCTASE INHIBITORS OF HIGH PURITY

Country Status (22)

Country Link
US (1) US6695969B1 (xx)
EP (1) EP1114040B1 (xx)
JP (1) JP3795755B2 (xx)
KR (1) KR100607608B1 (xx)
CN (1) CN1186335C (xx)
AT (1) ATE284396T1 (xx)
AU (1) AU766630B2 (xx)
BG (1) BG64676B1 (xx)
CA (1) CA2343645A1 (xx)
DE (1) DE69922519T2 (xx)
HR (1) HRP20010045B1 (xx)
HU (1) HUP0102997A2 (xx)
IL (2) IL142056A0 (xx)
IS (1) IS2149B (xx)
NZ (1) NZ509582A (xx)
PL (1) PL200336B1 (xx)
RO (1) RO121116B1 (xx)
RS (1) RS49996B (xx)
RU (1) RU2235098C2 (xx)
SI (1) SI20072A (xx)
SK (1) SK285868B6 (xx)
WO (1) WO2000017182A1 (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141602B2 (en) * 1998-09-18 2006-11-28 Lek Pharmaceuticals D.D. Process for obtaining HMG-CoA reductase inhibitors of high purity
SI20305A (sl) * 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristali natrijeve soli pravastatina
HUP9902352A1 (hu) * 1999-07-12 2000-09-28 Gyógyszerkutató Intézet Kft. Eljárás pravasztatin mikrobiológiai előállítására
CN1754872A (zh) * 1999-11-30 2006-04-05 特瓦药厂有限公司 从发酵肉汤中回收抑素化合物的方法
CN1434702A (zh) * 1999-12-14 2003-08-06 拜奥盖尔药厂有限公司 新的帕伐他丁钠形式
EP1265884A4 (en) 2000-03-03 2003-05-21 Plus Chemical S A PROCESS FOR THE PURIFICATION OF LOVASTATIN AND SIMVASTATIN FOR REDUCING THE CONTENT OF DIMER IMPURITIES
US6936731B2 (en) 2000-10-05 2005-08-30 TEVA Gyógyszergyár Részvénytársaság Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
US20050215636A1 (en) * 2000-10-05 2005-09-29 Vilmos Keri Pravastatin sodium substantially free of pravastatin lactone and EPI-pravastatin, and compositions containing same
AU2002211462A1 (en) * 2000-10-05 2002-04-22 Teva Gyogyszergyar Reszvenytarsasag Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
KR100407758B1 (ko) * 2001-08-27 2003-12-01 씨제이 주식회사 스타틴의 제조에 있어서 락톤화 방법
JP2003093045A (ja) * 2001-09-26 2003-04-02 Godo Shusei Co Ltd 有用変換微生物
KR100435078B1 (ko) * 2002-02-08 2004-06-09 종근당바이오 주식회사 심바스타틴의 정제방법
WO2004087935A2 (en) * 2003-04-01 2004-10-14 Ranbaxy Laboratories Limited Fermentation process for the preparation of pravastatin
US6978908B2 (en) * 2003-09-15 2005-12-27 Gerber Products Company Drinking vessel with adjustable handles
DE04811862T1 (de) * 2003-11-24 2006-03-02 Teva Gyogyszergyar Reszvenytarsasag Verfahren zur Reinigung von Pravastatin
ES2239533B1 (es) * 2004-03-01 2006-12-16 Ercros Industrial, S.A. Procedimiento para la obtencion de compactina.
CN101124230A (zh) * 2004-09-28 2008-02-13 特瓦制药工业有限公司 制备基本无杂质的阿托伐他汀钙形式的方法
CN102043030A (zh) * 2009-10-22 2011-05-04 北京万全阳光医学技术有限公司 一种用高效液相色谱法测定烟酸辛伐他汀缓释片有关物质的方法
CN102621238A (zh) * 2011-02-01 2012-08-01 北京北大维信生物科技有限公司 一种测定HMG-CoA还原酶抑制剂浓度的方法
CN105985244A (zh) * 2015-02-04 2016-10-05 北京北大维信生物科技有限公司 化合物、其分离方法、合成方法及用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
IT1232311B (it) 1989-09-04 1992-01-28 Sclavo Spa Metodo di purificazione di composti a struttura peptidica o pseudo peptidica a basso peso molecolare.
US5202029A (en) * 1991-03-13 1993-04-13 Caron Kabushiki Kaisha Process for purification of hmg-coa reductase inhibitors
EP0575616A4 (en) * 1991-03-14 1996-07-10 Ace Denken Kk Stock control system
US5420024A (en) * 1993-05-11 1995-05-30 Merck & Co., Inc. Process for synthesis of acylated HMG-CoA reductase inhibitors from a lactone diol precursor using Candida cylindracea
US5427686A (en) 1994-04-05 1995-06-27 Sri International Process for separating material from mixture using displacement chromatography
EP0877089A1 (en) * 1997-05-07 1998-11-11 Gist-Brocades B.V. HMG-CoA reductase inhibitor preparation process

Also Published As

Publication number Publication date
IL142056A (en) 2006-08-01
JP3795755B2 (ja) 2006-07-12
US6695969B1 (en) 2004-02-24
RU2235098C2 (ru) 2004-08-27
PL345883A1 (en) 2002-01-14
WO2000017182A1 (en) 2000-03-30
AU766630B2 (en) 2003-10-23
EP1114040A1 (en) 2001-07-11
EP1114040B1 (en) 2004-12-08
SK20022000A3 (sk) 2001-08-06
RS49996B (sr) 2008-09-29
IL142056A0 (en) 2002-03-10
ATE284396T1 (de) 2004-12-15
IS5886A (is) 2001-03-12
CA2343645A1 (en) 2000-03-30
PL200336B1 (pl) 2008-12-31
SK285868B6 (sk) 2007-10-04
HUP0102997A2 (hu) 2001-12-28
BG105348A (en) 2001-11-30
NZ509582A (en) 2003-10-31
CN1186335C (zh) 2005-01-26
KR100607608B1 (ko) 2006-08-02
RO121116B1 (ro) 2006-12-29
YU81800A (sh) 2003-02-28
CN1318063A (zh) 2001-10-17
HRP20010045A2 (en) 2001-12-31
DE69922519T2 (de) 2005-12-08
AU5528499A (en) 2000-04-10
DE69922519D1 (de) 2005-01-13
BG64676B1 (bg) 2005-11-30
IS2149B (is) 2006-10-13
SI20072A (sl) 2000-04-30
JP2002526486A (ja) 2002-08-20
KR20010099584A (ko) 2001-11-09

Similar Documents

Publication Publication Date Title
IL142056A0 (en) Process for obtaining hmg-coa reductase inhibitors of high purity
IL187261A0 (en) Crystals of the sodium salt of pravastatin
IL142055A0 (en) New salts of hmg-coa reductase inhibitors
IL143759A0 (en) STABLE PHARMACEUTICAL FORMULATION COMPRISING HMG-CoA REDUCTASE INHIBITORS
AU4943400A (en) Stabilized pharmaceutically effective composition and pharmaceutical formulationcomprising the same
AU1510800A (en) Process for the preparation of simvastatin and analogs thereof
AU2000250960A1 (en) Stable pharmaceutical product and formulation
NZ535910A (en) Preparation of amorphous HMG-CoA reductase inhibitors and hydrates thereof by dissolving a heterogeneous mixture of the enzyme in a hydroxylic solvent and freeze drying
Misra Fungi and statins
YU88602A (sh) Stabilizovane farmaceutski efektivne smeše i farmaceutske formulacije koje ih sadrže
WO2002100323A3 (en) METHYL ANALOGS OF SIMVASTATIN AS NOVEL HMG-CoA REDUCTASE INHIBITORS

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20120803

Year of fee payment: 14

PBON Lapse due to non-payment of renewal fee

Effective date: 20130917